Literature DB >> 12388830

Purine nucleoside phosphorylase as a cytosolic arsenate reductase.

Zoltán Gregus1, Balázs Németi.   

Abstract

The findings of the accompanying paper (Németi and Gregus, Toxicol: Sci. 70, 4-12) indicate that the arsenate (AsV) reductase activity of rat liver cytosol is due to an SH enzyme that uses phosphate (or its analogue, arsenate, AsV) and a purine nucleoside (guanosine or inosine) as substrates. Purine nucleoside phosphorylase (PNP) is such an enzyme. It catalyzes the phosphorolytic cleavage of 6-oxopurine nucleosides according to the following scheme: guanosine (or inosine) + phosphate <--> guanine (or hypoxanthine) + ribose-1-phosphate. Therefore, we have tested the hypothesis that PNP is responsible for the thiol- and purine nucleoside-dependent reduction of AsV to AsIII by rat liver cytosol. AsIII formed from AsV was quantified by HPLC-hydride generation-atomic fluorescence spectrometry analysis of the deproteinized incubates. The following findings support the conclusion that PNP reduces AsV to AsIII, using AsV instead of phosphate in the reaction above: (1) Specific PNP inhibitors (CI-1000, BCX-1777) at a concentration of 1 microM completely inhibited cytosolic AsV reductase activity. (2) During anion-exchange chromatography of cytosolic proteins, PNP activity perfectly coeluted with the AsV reductase activity, suggesting that both activities belong to the same protein. (3) PNP purified from calf spleen catalyzed reduction of AsV to AsIII in the presence of dithiothreitol (DTT) and a 6-oxopurine nucleoside (guanosine or inosine). (4) AsV reductase activity of purified PNP, like the cytosolic AsV reductase activity, was inhibited by phosphate (a substrate of PNP alternative to AsV), guanine and hypoxanthine (products of PNP favoring the reverse reaction), mercurial thiol reagents (nonspecific inhibitors of PNP), as well as CI-1000 and BCX-1777 (specific PNP inhibitors). Thus, PNP appears to be responsible for the AsV reductase activity of rat liver cytosol in the presence of DTT. Further research should clarify the mechanism and the in vivo significance of PNP-catalyzed reduction of AsV to AsIII.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12388830     DOI: 10.1093/toxsci/70.1.13

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  15 in total

1.  Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1.

Authors:  Helen Denton; Joanne C McGregor; Graham H Coombs
Journal:  Biochem J       Date:  2004-07-15       Impact factor: 3.857

Review 2.  Individual susceptibility to arsenic-induced diseases: the role of host genetics, nutritional status, and the gut microbiome.

Authors:  Liang Chi; Bei Gao; Pengcheng Tu; Chih-Wei Liu; Jingchuan Xue; Yunjia Lai; Hongyu Ru; Kun Lu
Journal:  Mamm Genome       Date:  2018-02-10       Impact factor: 2.957

Review 3.  Effects of arsenic exposure on DNA methylation and epigenetic gene regulation.

Authors:  John F Reichard; Alvaro Puga
Journal:  Epigenomics       Date:  2010-02       Impact factor: 4.778

4.  shRNA silencing of AS3MT expression minimizes arsenic methylation capacity of HepG2 cells.

Authors:  Zuzana Drobna; Weibing Xing; David J Thomas; Miroslav Stýblo
Journal:  Chem Res Toxicol       Date:  2006-07       Impact factor: 3.739

5.  Metabolism and toxicity of arsenic in human urothelial cells expressing rat arsenic (+3 oxidation state)-methyltransferase.

Authors:  Zuzana Drobná; Stephen B Waters; Vicenta Devesa; Anne W Harmon; David J Thomas; Miroslav Stýblo
Journal:  Toxicol Appl Pharmacol       Date:  2005-09-01       Impact factor: 4.219

Review 6.  Liver is a target of arsenic carcinogenesis.

Authors:  Jie Liu; Michael P Waalkes
Journal:  Toxicol Sci       Date:  2008-06-19       Impact factor: 4.849

7.  Development of a human physiologically based pharmacokinetic (PBPK) model for inorganic arsenic and its mono- and di-methylated metabolites.

Authors:  Hisham A El-Masri; Elaina M Kenyon
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-10-18       Impact factor: 2.745

8.  Interaction between arsenic exposure from drinking water and genetic susceptibility in carotid intima-media thickness in Bangladesh.

Authors:  Fen Wu; Farzana Jasmine; Muhammad G Kibriya; Mengling Liu; Xin Cheng; Faruque Parvez; Rachelle Paul-Brutus; Rina Rani Paul; Golam Sarwar; Alauddin Ahmed; Jieying Jiang; Tariqul Islam; Vesna Slavkovich; Tatjana Rundek; Ryan T Demmer; Moise Desvarieux; Habibul Ahsan; Yu Chen
Journal:  Toxicol Appl Pharmacol       Date:  2014-03-02       Impact factor: 4.219

9.  Differential effect of Taraxacum officinale L. (dandelion) root extract on hepatic and testicular tissues of rats exposed to ionizing radiation.

Authors:  Nadia Abdel-Magied; Salma M Abdel Fattah; Ahmed A Elkady
Journal:  Mol Biol Rep       Date:  2019-06-28       Impact factor: 2.316

Review 10.  Realgar (α-As4S4) Treats Myelodysplastic Syndromes through Reducing DNA Hypermethylation.

Authors:  Miao Zhang; Jia-Yi Zhang; Ming-Qian Sun; Peng Lu; Jian-Xun Liu
Journal:  Chin J Integr Med       Date:  2020-05-16       Impact factor: 1.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.